TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04657913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold water spray application
Description: It will be sprayed into the mouth of patients every hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold saline spray application
Description: It will be sprayed into the mouth of patients every hour.
Study: NCT02696616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655088

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03540108

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Maltodextrin
Description: Please see intervention description above.
Study: NCT05331560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Pulse Stimulation (TPS)
Description: A global brain stimulation approach, which homogenously distributes the total energy of 6000 TPS pulses per session over all accessible brain areas.~Prefrontal, Temporal and Occipital brain areas were stimulated by ultrashort (3μs) ultrasound pulses with typical energy levels of 0.2-0.25 mJ/mm2 and pulse frequencies of 4-5 Hz (pulses per second).
Study: NCT02563314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive mechanical ventilation - Normoxia
Description: Maintenance of an oxygen setting allowing normal oxygen saturation during non-invasive mechanical ventilation (SpO2 targeted 96-98%)

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive mechanical ventilation - Controlled hypoxemia
Description: Maintenance of an oxygen setting allowing mild hypoxemia during non-invasive mechanical ventilation (SpO2 targeted 88-92%)
Study: NCT00498914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM155
Description: Continuous IV infusion
Study: NCT04811742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bathing
Description: immerson bathing and showering

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bathing
Description: immerson bathing and showering
Study: NCT03749759

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: A biofeedback measurement will be carried out during cataract surgery of both eyes
Study: NCT02967653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Member of drug class called statins, primarily used as a lipid-lowering agent and the prevention of events associated with cardiovascular disease

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Member of drug class called statins, primarily used as a lipid-lowering agent and the prevention of events associated with cardiovascular disease
Study: NCT04365712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezoelectric tool

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oscillating Saw
Study: NCT01276639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 10 mg oral BID, Continuous treatment for 52 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 5 mg oral BID, Continuous treatment for 52 Weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/CP-690,550
Description: 0 mg oral BID, Continuous treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/CP-690,550
Description: 0 mg oral BID, Continuous treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
Study: NCT03868033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Use Zoledronic acid as a sequential therapy after denosumab treatment for more than 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Use Zoledronic acid as a sequential therapy after denosumab treatment for more than 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Use Zoledronic acid as a sequential therapy after denosumab treatment for more than 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Continuous Denosumab treatment in arm 1 for two years or as a 2nd year treatment in arm 2 for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Continuous Denosumab treatment in arm 1 for two years or as a 2nd year treatment in arm 2 for one year
Study: NCT00390767

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiGeneAngio
Description: Escalating doses of MultiGeneAngio, one dose per patient administered as one treatment, infused intra-arterially
Study: NCT03647657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PP-F11N
Description: Intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and without co-medication with Sacuitril (100 mg Entresto) in each patient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PP-F11N
Description: Intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and without co-medication with Sacuitril (100 mg Entresto) in each patient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacuitril
Description: Medication with Sacuitril (100 mg Entresto) additional to the injection of 177Lu-PP-F11N

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacuitril
Description: Medication with Sacuitril (100 mg Entresto) additional to the injection of 177Lu-PP-F11N
Study: NCT02568514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Secure text messaging
Description: A smartphone and web application that allows physicians and other health care professionals to communicate to each other by secure text message
Study: NCT00566423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Venous and Arterial Blood draw samples; 6 Minute Walk test
Study: NCT04552769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 200 mg orally
Study: NCT02423655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm for deferred dialysis intervention
Description: Use combined indications to guide researchers to defer dialyzing progressive CKD patients. Asymptomatic patient will not start dialysis treatment until his eGFR becomes less than 5 ml/min/1.73m2. Or until 1. Patient's Kraemer index is \>6 or with overt fluid overload after trying all conservative means（including appropriate medicines） 2. Patient's Subjective Global Assessment method (SGA) assessment is grade C 3. Patients have indications for emergency dialysis 4. Sever symptoms which cannot be relieved by conservative treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Algorithm for routine dialysis intervention
Description: Use combined indications to guide researchers to initiate dialysis in progressive CKD patients routinely. Researchers will start dialysis treatment for a patient when his eGFR reaches 7 ml/min/1.73m2 in asymptomatic patients.~Or patients have indications below: 1. Patient's Kraemer index is \>6 or with overt fluid overload after trying all conservative means（including appropriate medicines） 2. Patient's SGA assessment is grade C 3. Patients have indications for emergency dialysis 4. Sever symptoms which cannot be relieved by conservative treatment
Study: NCT01518556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: In the phase I study, idarubicin dose is increased step by step as follows: 12 mg/m2/day for 3 days IV in the 1st step; 15 mg/m2/day for 3 days IV in the 2nd step; 18 mg/m2/day for 3 days IV in the 3rd step.~In the phase II study, idarubicin dose is the maximum tolerated dose that is determined from the phase I study or 18 mg/m2/day for 3 days .
Study: NCT03835299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear Intervention
Description: Coping information related to the fear that was identified by the participant will be presented via a computer tablet.
Study: NCT00605124

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knee muscle exercises
Description: Home exercises three times a week, control every three months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee muscle exercises
Description: Home exercises three times a week, control every three months
Study: NCT02469623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dipole Density Mapping with AcQMap followed by ablation
Study: NCT04690140

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epithelialized free gingival graft
Description: The Epithelialized free gingival graft placed on the prepared bed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified coronally advanced tunnel technique
Description: Connective tissue graft placed under the prepared tunnel
Study: NCT02836652

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartMate II (HMII)
Description: Left Ventricular Assist Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMate II (HMII)
Description: Left Ventricular Assist Device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: (INR Target 2.0-2.5, median 2.25, per standard of patient care)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: (INR Target 2.0-2.5, median 2.25, per standard of patient care)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid (ASA) therapy
Description: (81mg/day)
Study: NCT01169948

Intervention type: RADIATION
Intervention: Computed tomography scan
Description: Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and myocardial perfusion scanning.
Study: NCT00587158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: Zemplar® - this medicine, which is the medicine being studied, will be given as a capsule containing 1 microgram of Zemplar® once daily beginning the day after the transplant. It will be continued at the same dose for the first two weeks then, depending on the results of blood and urine testing, will be increased to 2 micrograms daily. The dose will remain at 2 micrograms daily until the end of the study unless there is a medical reason to reduce or stop it or unless the study is stopped early.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Avoidance Immune Suppression Protocol
Description: Induction with Alemtuzumab and maintenance with Tacrolimus and Mycophenolate Mofetil. With standard antimicrobial prophylaxis and calcium supplementation.

Intervention type: OTHER
Group type: OTHER
Intervention: Corticosteroid Avoidance Immune Suppression Protocol
Description: Induction with Alemtuzumab and maintenance with Tacrolimus and Mycophenolate Mofetil. With standard antimicrobial prophylaxis and calcium supplementation.
Study: NCT01153867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Schema Focused Therapy
Description: SFT is a novel treatment approach to chronic, lifelong problems that incorporates cognitive, behavioral, experiential and psychodynamic elements and techniques. In the present study participants will receive up to 75 individual sessions of SFT depending on the individual progress in therapy.
Study: NCT04033744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extraction of mandibular third molar
Description: After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle. An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: extraction of mandibular third molar
Description: After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle. An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary
Study: NCT03741972

Intervention type: DRUG
Intervention: iSGTL2
Description: Treatment with empaglifozine 10 mg/day (may be also dapaglifozine 10mg/day depending on clinical trial results)
Study: NCT02938195

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: The clinical target volume of radiotherapy only includes the visible tumor and lymph nodes and the investigators wouldn't do any prophylactic radiation treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery would be done 4-8 weeks after neoadjuvant chemoradiotherapy.
Study: NCT04115384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novolin-R insulin
Description: Insulin (Novolin-R) 20 IU/IN (0.1ml/10 units IN in each nostril), twice per day, once in the morning and again in the evening (at least 8 hours between doses) for 4 weeks.
Study: NCT03324243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib
Description: 66.7 mg/m2 three times a day (TID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2/day, intravenous infusions over 30 mins.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2000 mg/m2/day, intravenous infusions over 1-3 hours.
Study: NCT00250237

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Haloperidol 1mg twice daily during 72hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo 1mg twice daily during 72hours
Study: NCT00088140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDN-6556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDN-6556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDN-6556

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03573141

Intervention type: OTHER
Intervention: Physical Therapy
Description: Subjects received a comprehensive physical therapy evaluation after baseline data collection and received a normal course pf physical therapy treatment based on impairments identified.
Study: NCT03335735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss-framed text message
Description: Participants in the intervention group will receive loss-framed text messages related to drinking and driving on days during the week with a higher likelihood of alcohol consumption (Thursday-Saturday). Loss aversion refers to people's tendency to prefer avoiding losses to acquiring equivalent gains: it's better to not lose $5 than to find $5, so the content of the messages will be related to loss of personal freedom, loss of money, and loss of future employment opportunities due to Driving Under the Influence (DUI) convictions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain-Framed text message
Description: Participants in the intervention group will receive gain-framed text messages related to drinking and driving on days during the week with a higher likelihood of alcohol consumption (Thursday-Saturday). Gain-framed messages have been shown to have a positive effect on preventative healthcare and include content framed in a manner that the participant gains something from taking preventative action. Message content will be related to saving lives, gaining control, and making loved ones happy.
Study: NCT00496080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doppler-Guided Uterine Artery Occlusion Device (DUAO)
Description: Investigational transvaginal clamp inserted one time for 6 hours.
Study: NCT04137913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Musical arts intervention
Description: A 6-week group music class that incorporates listening, theory, performance, and creation of music.
Study: NCT03287999

Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombophilia screen
Description: Thrombophilia screen (including antithrombin activity (AT:Ac), protein S antigen (PS:free), protein C activity (PC:Ac) , genetic analysis for FV Leiden and Prothrombin 3'UTR mutations and screening for lupus anticoagulant.

Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombophilia screen
Description: Thrombophilia screen (including antithrombin activity (AT:Ac), protein S antigen (PS:free), protein C activity (PC:Ac) , genetic analysis for FV Leiden and Prothrombin 3'UTR mutations and screening for lupus anticoagulant.

Intervention type: DIAGNOSTIC_TEST
Intervention: Initiation pathway analysis
Description: Evaluation of inter-individual variability in regulation of TF.VIIa.Xa.TFPI complex (tissue factor, activated Factor VII, activated factor X, tissue factor pathway inhibitor)

Intervention type: DIAGNOSTIC_TEST
Intervention: Initiation pathway analysis
Description: Evaluation of inter-individual variability in regulation of TF.VIIa.Xa.TFPI complex (tissue factor, activated Factor VII, activated factor X, tissue factor pathway inhibitor)
Study: NCT00918177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP09004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP09004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa/Levodopa, immediate release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa/Levodopa, immediate release
Study: NCT00878956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate
Description: In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
Study: NCT01865760

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral Glucose tolerance test (OGGT)
Description: At baseline subjects will consume 50 g glucose dissolved in water in 10 minutes

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose tolerance test (OGGT)
Description: At baseline subjects will consume 50 g glucose dissolved in water in 10 minutes

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Glucose tolerance test (OGGT)
Description: At baseline subjects will consume 50 g glucose dissolved in water in 10 minutes

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Liquid mixed meal
Description: At baseline subject will consume the liquid mixed meal in 10 minutes

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liquid mixed meal
Description: At baseline subject will consume the liquid mixed meal in 10 minutes

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid mixed meal
Description: At baseline subject will consume the liquid mixed meal in 10 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: At baseline subjects will receive Octreotid 100 µg subcutaneous
Study: NCT02339753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Blood sampling will be done at the time before administration (0hr pre-dose), 1hr, 2hr, 5hr for pharmacokinetic study.
Study: NCT00571155

Intervention type: DRUG
Group type: OTHER
Intervention: levetiracetam
Description: oral and intravenous dosing 2000-3000 mg per day
Study: NCT04365621

Intervention type: OTHER
Group type: OTHER
Intervention: we enrolled ultra-high risk of psychosis (UHR) patient to describe
Description: there is no intervention because we study only the prevalence of patients meeting UHR criteria
Study: NCT02147743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCP+MDFT
Description: Multidimensional Family Therapy (MDFT; Liddle, 2002) is one of a new generation of multi-systems oriented family-based intervention for adolescent substance abuse and delinquency. It has demonstrated considerable success with juvenile justice youth at various stages of their involvement in the justice system. The model has demonstrated efficacy in reducing substance use and delinquency, increasing the prosocial behaviors (e.g., family functioning, school outcomes) of substance abusing and court involved adolescents.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CCP+SAU
Description: Services As Usual community partners will provide individualized mental health counseling and psychiatric services, psychoeducational groups and substance abuse counseling.
Study: NCT03244917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRAIN-AD
Description: The study intervention is a multi-component training and education program targeting direct care providers and healthcare proxies for advanced dementia NH residents, intended to improve the management of urinary and lower respiratory tract infections in advanced dementia patients. There are two components to this practice intervention: 1. Provider Training, and 2. Proxy Education. Intervention components aimed at the provider include: Professionally led infection management training seminars, online infection management course, and infection management guidance algorithms. Additionally participating prescribing providers will be sent bimonthly infection management feedback reports. Proxy Education is completed by providing an infection management in Advanced Dementia booklet to proxies of patients with AD upon resident enrollment in study.
Study: NCT05888675

Intervention type: DRUG
Group type: OTHER
Intervention: Weifuchun
Description: The treatment group#Weifuchun group#was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and Ticeo monotherapy regimen.